4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine : A Randomized Clinical Trial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          0098-7484
          May 15 2018
          May 15 2018
          : 319
          : 19
          : 1999
          Affiliations
          [1 ]Mayo Clinic Arizona, Phoenix
          [2 ]Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania
          [3 ]Teva Pharmaceuticals, Frazer, Pennsylvania
          [4 ]NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College London, London, England
          Article
          10.1001/jama.2018.4853
          6583237
          29800211
          b10bb09d-74fb-4b80-9354-1b07d51eab4c
          © 2018
          History

          Comments

          Comment on this article